Amgen (BUE:AMGN) Inventories, Finished Goods : ARS2,128,155 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Amgen Inventories, Finished Goods?

Amgen's quarterly finished goods increased from Sep. 2023 (ARS414,691 Mil) to Dec. 2023 (ARS1,002,858 Mil) and increased from Dec. 2023 (ARS1,002,858 Mil) to Mar. 2024 (ARS2,128,155 Mil).

Amgen's annual finished goods increased from Dec. 2021 (ARS108,261 Mil) to Dec. 2022 (ARS168,321 Mil) and increased from Dec. 2022 (ARS168,321 Mil) to Dec. 2023 (ARS1,002,858 Mil).

Amgen Inventories, Finished Goods Historical Data

The historical data trend for Amgen's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Inventories, Finished Goods Chart

Amgen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Finished Goods

Get a 7-Day Free Trial

59,713.83

78,938.60

108,261.28

168,320.60

1,002,858.00

Amgen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Inventories, Finished Goods	Get a 7-Day Free Trial															223,231.51	258,000.00	414,690.76	1,002,858.00	2,128,155.04

Amgen Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Amgen (BUE:AMGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (BUE:AMGN) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMGN34:Brazil AMGN:Austria

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.